CLINICAL STUDY: HYPERTENSION
Cardiac fibrosis occurs early and involves endothelin and AT-1 receptors in hypertension due to endogenous angiotensin II
Teresa M. Seccia, MD*,
Anna S. Belloni, BSc ,
Reinhold Kreutz, MD ,
Martin Paul, MD ,
Gastone G. Nussdorfer, MD ,
Achille C. Pessina, MD, PhD and
Gian Paolo Rossi, MD, FACC ,*
* Department of Clinical Methodology and Clinical-Surgical Technologies, University of Bari, Bari, Italy
Department of Human Anatomy and Physiology (Section of Anatomy), University of Padova, Padova, Italy
Institute of Clinical Pharmacology and Toxicology, Freie University of Berlin, Berlin, Germany
Department of Clinical and Experimental Medicine, Clinica Medica 4, University of Padova, Padova, Italy
Manuscript received June 19, 2002;
accepted October 17, 2002.
* Reprint requests and correspondence: Dr. Gian Paolo Rossi, Dept. of Clinical and Experimental Medicine, Clinica Medica 4, University Hospital, via Giustiniani, 2, 35126 Padova, Italy. gianpaolo.rossi{at}unipd.it
OBJECTIVES: We investigated if endothelin (ET)-1 and the renin-angiotensin-aldosterone system play a role in cardiac fibrosis.
BACKGROUND: Angiotensin II (Ang II) can induce cardiac fibrosis, but the underlying mechanisms are incompletely understood.
METHODS: Four-week-old transgenic (mRen2)27 rat (TGRen2) received for four weeks a placebo, the mixed ETA/ETB endothelin receptor antagonist bosentan, the angiotensin II type I receptor (AT-1) antagonist irbesartan, the ETA endothelin receptor antagonist BMS-182874, and a combined treatment with irbesartan plus BMS-182874. We measured collagen density on Sirius redstained serial sections of the left ventricle (LV) with a photomicroscope equipped with specific software and assessed the gene expression of procollagen 1(I), atrial natriuretic peptide (ANP), transforming growth factor-beta 1 (TGFß1), endothelin converting enzyme, and ETB receptor.
RESULTS: In the placebo group, hypertension was associated with LV hypertrophy and cardiac fibrosis (LV weight: 4.0 ± 0.3 mg/g body weight; collagen density: 2.21 ± 0.16%), which were all prevented with irbesartan (2.3 ± 0.1, 1.30 ± 0.13, p < 0.001), but not with BMS-182874 (4.0 ± 0.2, 2.41 ± 0.22). Bosentan also prevented fibrosis (1.39 ± 0.18) but not hypertension and LV hypertrophy (3.38 ± 0.27). Combined irbesartan and BMS-182874 treatment prevented LV hypertrophy (2.9 ± 0.1) but not fibrosis (2.52 ± 0.16). Collagen density correlated (r = 0.414, p < 0.05) with plasma aldosterone levels. In TGRen2 with LV hypertrophy, the gene expression of ANP and ETB but not that of TGFß1 and procollagen 1(I) was increased.
CONCLUSIONS: In Ang IIdependent hypertension, cardiac fibrosis was associated with LV hypertrophy and was hindered by both mixed ETA/ETB blockade and AT-1 blockade. Only the latter treatment prevented both hypertension and LV hypertrophy. Thus, there is a dissociation between the mechanisms of cardiac fibrosis and hypertension, which do and do not entail ET-1, respectively.
|
Abbreviations and Acronyms
| | Ang II | | angiotensin II | | ANP | | atrial natriuretic peptide | | AT-1 | | angiotensin II type I receptor | | BP | | blood pressure | | BW | | body weight | | DOCA | | deoxycorticosterone acetate | | ET-1 | | endothelin-1 | | LV | | left ventricle | | RAAS | | renin-angiotensin-aldosterone system | | TGFß1 | | transforming growth factor-beta 1 | | TGRen2 | | transgenic (mRen2)27 rat | | 2K1C | | 2 kidney 1 clip model |
|
This article has been cited by other articles:

|
 |

|
 |
 
H. Pavlopoulos and P. Nihoyannopoulos
Regional left ventricular distribution of abnormal segmental relaxation evaluated by strain echocardiography and the incremental value over annular diastolic velocities in hypertensive patients with normal global diastolic function
Eur J Echocardiogr,
July 1, 2009;
10(5):
654 - 662.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. M. Luther, Z. Wang, J. Ma, N. Makhanova, H.-S. Kim, and N. J. Brown
Endogenous Aldosterone Contributes to Acute Angiotensin II-Stimulated Plasminogen Activator Inhibitor-1 and Preproendothelin-1 Expression in Heart But Not Aorta
Endocrinology,
May 1, 2009;
150(5):
2229 - 2236.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Conen, U. B. Tedrow, B. A. Koplan, R. J. Glynn, J. E. Buring, and C. M. Albert
Influence of Systolic and Diastolic Blood Pressure on the Risk of Incident Atrial Fibrillation in Women
Circulation,
April 28, 2009;
119(16):
2146 - 2152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Pavlopoulos, J. Grapsa, E. Stefanadi, V. Kamperidis, E. Philippou, D. Dawson, and P. Nihoyannopoulos
The evolution of diastolic dysfunction in the hypertensive disease
Eur J Echocardiogr,
November 1, 2008;
9(6):
772 - 778.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. F. Opitz, R. Ewert, W. Kirch, and D. Pittrow
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Eur. Heart J.,
August 2, 2008;
29(16):
1936 - 1948.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Whaley-Connell, J. Habibi, S. A. Cooper, V. G. DeMarco, M. R. Hayden, C. S. Stump, D. Link, C. M. Ferrario, and J. R. Sowers
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat
Am J Physiol Endocrinol Metab,
July 1, 2008;
295(1):
E103 - E109.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. G. DeMarco, J. Habibi, A. T. Whaley-Connell, R. I. Schneider, R. L. Heller, J. P. Bosanquet, M. R. Hayden, K. Delcour, S. A. Cooper, B. T. Andresen, et al.
Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat
Am J Physiol Heart Circ Physiol,
June 1, 2008;
294(6):
H2659 - H2668.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Wong, F. E. Brennan, M. J. Young, P. J. Fuller, and T. J. Cole
A Direct Effect of Aldosterone on Endothelin-1 Gene Expression in Vivo
Endocrinology,
April 1, 2007;
148(4):
1511 - 1517.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. A. Gould, M. Yii, M. D. Esler, J. M. Power, and D. M. Kaye
Atrial fibrillation impairs cardiac sympathetic response to baroreceptor unloading in congestive heart failure
Eur. Heart J.,
December 1, 2005;
26(23):
2562 - 2567.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. A. Thackaberry, Z. Jiang, C. D. Johnson, K. S. Ramos, and M. K. Walker
Toxicogenomic Profile of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in the Murine Fetal Heart: Modulation of Cell Cycle and Extracellular Matrix Genes
Toxicol. Sci.,
November 1, 2005;
88(1):
231 - 241.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Vaneckova, H. J. Kramer, A. Backer, Z. Vernerova, M. Opocensky, and L. Cervenka
Early Endothelin-A Receptor Blockade Decreases Blood Pressure and Ameliorates End-Organ Damage in Homozygous Ren-2 Rats
Hypertension,
October 1, 2005;
46(4):
969 - 974.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Milliez, X. Girerd, P.-F. Plouin, J. Blacher, M. E. Safar, and J.-J. Mourad
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism
J. Am. Coll. Cardiol.,
April 19, 2005;
45(8):
1243 - 1248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. M. Pollock
Endothelin, Angiotensin, and Oxidative Stress in Hypertension
Hypertension,
April 1, 2005;
45(4):
477 - 480.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Tikellis, P. J. Wookey, R. Candido, S. Andrikopoulos, M. C. Thomas, and M. E. Cooper
Improved Islet Morphology after Blockade of the Renin- Angiotensin System in the ZDF Rat
Diabetes,
April 1, 2004;
53(4):
989 - 997.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. G Perez, M. C Villa-Abrille, E. A Aiello, R. A Dulce, H. E Cingolani, and M. C Camilion de Hurtado
A low dose of angiotensin II increases inotropism through activation of reverse Na+/Ca2+ exchange by endothelin release
Cardiovasc Res,
December 1, 2003;
60(3):
589 - 597.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T.-H. Cheng, P.-Y. Cheng, N.-L. Shih, I.-B. Chen, D. L. Wang, and J.-J. Chen
Involvement of reactive oxygen species in angiotensin II-induced endothelin-1 gene expression in rat cardiac fibroblasts
J. Am. Coll. Cardiol.,
November 19, 2003;
42(10):
1845 - 1854.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q. Pu, M. F. Neves, A. Virdis, R. M. Touyz, and E. L. Schiffrin
Endothelin Antagonism on Aldosterone-Induced Oxidative Stress and Vascular Remodeling
Hypertension,
July 1, 2003;
42(1):
49 - 55.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|